Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris (Nasdaq: VTRS) announced the launch of Inpefa (sotagliflozin) in the United Arab Emirates, the first market within Viatris territories to commercialize the drug, with additional launches planned across multiple countries over the next several years.
Inpefa is the first dual SGLT1/2 inhibitor approved to reduce risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits. Approval is supported by two Phase 3 trials (SOLOIST-WHF and SCORED; >11,800 patients) showing a 33% reduction in the composite endpoint in SOLOIST-WHF (up to 51% when initiated prior to discharge), 25% reduction in SCORED, and a 23% reduction in MACE, including 32% reduction in MI and 34% reduction in stroke.
Aon (NYSE: AON) launched Resilience Quotient, a data-driven framework that combines Aon's Risk Capital and Human Capital analytics with Gallup World Poll sentiment data (covering 140 countries over 20+ years) to give a portfolio view of risk and resilience.
The tool maps how four megatrends—Trade, Technology, Weather and Workforce—compound risk, offers three case studies (data center growth with a $1.3 trillion 2030 data‑center investment projection, AI workforce transformation, and humanitarian finance for forced migration), and is delivered via a real-time, AI-enabled analytics platform built by Quantum Rise. Aon and Gallup will discuss the work at the World Economic Forum Annual Meeting.
Viatris (Nasdaq: VTRS) appointed Lara Ramsburg as Chief People and Corporate Affairs Officer effective Jan. 8, 2026. The newly combined role will align internal people functions with external corporate affairs to advance culture, stakeholder communication and sustainability priorities. Ramsburg brings more than 25 years of experience and has led Viatris corporate affairs since 2019, previously serving in the Office of the CEO and as Head of Integration. Responsibilities now include global talent, total rewards, employee experience, people solutions and HR business partners.
Viatris (Nasdaq: VTRS) reported four regulatory milestones across its global pipeline on Dec 18, 2025: FDA approval of a generic octreotide acetate injectable suspension (generic Sandostatin LAR Depot); FDA acceptance of an NDA for a low dose estrogen weekly contraceptive patch with a PDUFA date of July 30, 2026; FDA clearance of an IND for MR-146 AAV gene therapy with a planned Phase 1/2 CORVITA trial in H1 2026; and PMDA acceptance of a J-NDA for pitolisant in obstructive sleep apnea syndrome, with a J-NDA for narcolepsy still on track by year-end.
These items advance development and regulatory pathways across generics, women’s health, ophthalmology gene therapy, and sleep-disorder franchises.
Viatris (Nasdaq: VTRS) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026. The company's presentation and fireside chat begin at 9:00 a.m. PT / 12:00 p.m. ET. A live webcast will stream at investor.viatris.com, and an archived recording will be available at the same location for a limited time after the event.
Viatris (Nasdaq: VTRS) will participate in two investor conferences in early December 2025.
The company will take part in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 8:30 a.m. ET, and a fireside chat at the Evercore 8th Annual Healthcare Conference on December 3, 2025 at 8:45 a.m. ET. Both sessions will be available live and archived at investor.viatris.com for a limited time.
Viatris (Nasdaq: VTRS) announced it was named one of the Fortune World's Best Workplaces™ 2025 on November 13, 2025.
The list of 25 global leaders was selected from organizations that completed Great Place To Work’s employee survey, which gathered over 9 million responses representing more than 25 million employees. Eligibility required 5,000+ global employees and recognition on at least five regional Best Workplaces lists in 2024 or early 2025. Viatris highlighted employee feedback, wellbeing, inclusion, and its transformation since founding. The company pointed to related recognitions and its 2024 Sustainability Report for details on people and community initiatives.
Viatris (Nasdaq: VTRS) reported third-quarter 2025 results and updated full-year guidance on Nov 6, 2025.
Key Q3 metrics: Total revenues $3.76B (flat YoY), Adjusted EBITDA $1.155B (down 10% YoY), Adjusted EPS $0.67 (down 11% YoY), U.S. GAAP net loss $(128)M. The company generated $744.9M operating cash and $658.1M free cash flow in Q3.
Business updates include the acquisition of Aculys Pharma (pitolisant and Spydia rights in Japan/APAC), FDA approval of Iron Sucrose Injection, NDA submission for a low-dose estrogen weekly patch (expect mid-2026 approval), and >$920M returned to shareholders YTD including $500M in buybacks. Guidance ranges for 2025 revenues, adjusted EBITDA and adjusted EPS were raised and narrowed.
Viatris (Nasdaq: VTRS) announced a quarterly dividend of $0.12 per share, declared by the board on November 3, 2025. The dividend is payable on December 15, 2025 to shareholders of record at the close of business on November 24, 2025. This provides a concrete cash return timetable for VTRS shareholders.
Locus Biosciences announced a research collaboration with Viatris (NASDAQ: VTRS) on October 28, 2025 to develop precision engineered bacteriophage therapeutics for serious ophthalmic bacterial infections.
The collaboration will apply Locus’s platform—predictive AI, high-throughput robotics, and synthetic biology—to create bacteriophage cocktails aimed at selectively eliminating eye-pathogenic bacteria while sparing beneficial species. The program targets infections complicated by rising antibiotic resistance and seeks to advance phage-based alternatives or complements to traditional antibiotics.